<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oral formulations of <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">mesalazine</z:chebi>) appear less toxic than sulphasalazine </plain></SENT>
<SENT sid="1" pm="."><plain>We have therefore compared sulphasalazine, low dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> and high dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> in the treatment of mild to moderate relapse of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Sixty one patients (32 men, aged 20-78 years) were randomly allocated to sulphasalazine 2 g daily, <z:chebi fb="0" ids="6775">mesalazine</z:chebi> 800 mg daily, or <z:chebi fb="0" ids="6775">mesalazine</z:chebi> 2.4 g daily in a double blind, double dummy, four week trial </plain></SENT>
<SENT sid="3" pm="."><plain>Groups were comparable for age, sex, extent of disease, and pretrial sulphasalazine intake </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients were unable to complete the study because of treatment failure (two taking sulphasalazine and two high dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>A further two patients taking sulphasalazine developed side effects necessitating withdrawal </plain></SENT>
<SENT sid="6" pm="."><plain>Within treatment comparisons revealed significant improvement of: sigmoidoscopic grade in the sulphasalazine group; <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo>, sigmoidoscopic and histological grade in the low dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> group; stool frequency, <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo> and sigmoidoscopic grade in the high dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> group </plain></SENT>
<SENT sid="7" pm="."><plain>Greater improvement in <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo> (p less than 0.05) and sigmoidoscopic appearances (p less than 0.05) occurred in patients taking high dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> than in those taking sulphasalazine </plain></SENT>
<SENT sid="8" pm="."><plain>In two patients taking high dose <z:chebi fb="0" ids="6775">mesalazine</z:chebi> minor rises of plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> concentrations occurred, suggesting the need to monitor renal function </plain></SENT>
</text></document>